Atlas Legacy Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Atlas Legacy Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,569	Closed	-$216K	–	216
2026 Q1	$216K	Buy	+3,569	New	+$208K	0.04%	186

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Atlas Legacy Advisors's BMY Position: Q2 2026 in Review

Atlas Legacy Advisors sold out of Bristol-Myers Squibb (BMY) in Q2 2026, closing a stake of 3,569 shares — an estimated $216K sold.

Atlas Legacy Advisors first reported a position in BMY in Q1 2026 and held it in 1 quarter. The position peaked at $216K in Q1 2026. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Atlas Legacy Advisors reported no remaining Bristol-Myers Squibb position as of Q2 2026 after selling out during the quarter.
Atlas Legacy Advisors sold 3,569 Bristol-Myers Squibb shares in Q2 2026, an estimated $216K.
Atlas Legacy Advisors first reported a position in Bristol-Myers Squibb in Q1 2026 and held it in 1 quarter.
Atlas Legacy Advisors's Bristol-Myers Squibb position peaked at $216K in Q1 2026.
2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Atlas Legacy Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.